Treatment of metastatic tumors of the urogenital area with cytokine-induced killer cells
Treatment of metastatic tumors of the urogenital area using autologous cytokine-induced killer cells
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Autologous cytokine-induced killer cells injected intravenously
Standard treatment of bladder/renal cancer according to the Clinical protocols
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Minsk, Belarus
The relapse-free survival
The duration of relapse-free survival
Time frame: 1 year
The relapse-free survival
The duration of relapse-free survival
Time frame: 2 year
The relapse-free survival
The duration of relapse-free survival
Time frame: 3 year
Adverse effects associated with the therapy
Determination of adverse effects associated with the therapy
Time frame: 1 month
Adverse effects associated with the therapy
Determination of adverse effects associated with the therapy
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.